


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 491/056, A61K 31/44, C07D 498/04, 513/04, 495/04, 493/04 // (C07D 491/056, 319:00, 209:00) (C07D 491/056, 319:00, 231:00) (C07D 491/056, 319:00, 235:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/23485 (43) International Publication Date: 3 July 1997 (03.07.97)</p>
<p>(21) International Application Number: PCT/EP96/05637 (22) International Filing Date: 16 December 1996 (16.12.96) (30) Priority Data: 9526495.8 23 December 1995 (23.12.95) GB (71) Applicant (for all designated States except US): KNOLL AKTIENGESELLSCHAFT [DE/DE]; Knollstrasse, D-67061 Ludwigshafen (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): BIRCH, Alan, Martin [GB/GB]; Pennyfoot Street 4, Nottingham NG1 1GF (GB). BRADLEY, Paul, Anthony [GB/GB]; Pennyfoot Street 4, Nottingham NG1 1GF (GB). GILL, Julie, Carolyn [GB/GB]; Pennyfoot Street 4, Nottingham NG1 1GF (GB). (74) Agents: CRAWLEY, Karen, Anne et al.; BASF Aktiengesellschaft, D-67056 Ludwigshafen (DE).</p>		<p>(81) Designated States: AU, BG, BR, CA, CN, CZ, GE, HU, IL, JP, KR, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: HETEROARYLCARBOXAMIDE DERIVATIVES (57) Abstract Compounds of formula (I) and pharmaceutically acceptable salts thereof in which A is methylene or -O-; B is methylene or -O-; G₁-G₂-G₃ form a heteroaromatic chain; g is 0, 1 or 2; U is an alkylene chain optionally substituted by one or more alkyl; Q represents a divalent group containing nitrogen atoms; and T represents CO.HET, have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.</p> <div style="text-align: right;">  <p>(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	M	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

HETEROARYLCARBOXAMIDE DERIVATIVES

The present invention relates to novel heteroarylcarboxamide compounds which have affinity for 5-HT_{1A} and/or α_1 and/or D₂-like (D₂, D₃ and D₄ sub-types) receptors, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.

The present invention provides compounds of formula I



including enantiomers and pharmaceutically acceptable salts thereof in which

A is methylene or -O-;

20

B is methylene or -O-;

G₁-G₂-G₃ represent -N(R')-C(R'')=N-, -N=C(R'')-N(R')-, -N(R')-C(R'')=C(R''')-,
-C(R''')=C(R'')-N(R')-, -N(R')-N=C(R'')-, -C(R'')=N-N(R')-, -N(R')-N=N-, -N=N-N(R')-,
25 -N=C(R'')-O-, -N=C(R'')-S-, -O-C(R'')=N-, -S-C(R'')=N-, -O-N=C(R'')-, -S-N=C(R'')-,
-C(R'')=N-O-, -C(R'')=N-S-, -S-C(R'')=C(R''')-, -C(R'')=C(R''')-S-, -O-C(R'')=C(R''')-,
or -C(R'')=C(R''')-O-;

R' is H or an alkyl group containing 1 to 3 carbon atoms;

30

R'' and R''', which are the same or different, are H; halo; an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo; carboxy; an alkanoyl group containing 1 to 6 carbon atoms; an alkoxycarbonyl group in which the alkoxy group contains 1 to 3 carbon atoms; formyl; cyano; or a carbamoyl group or
 5 carbamoylmethyl group each optionally *N*-substituted by one or two alkyl groups, which may be the same or different, each containing 1 to 3 carbon atoms;

g is 0, 1 or 2;

10 R₁ represents an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo; an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo; halo; or an alkylthio group containing 1 to 3 carbon atoms optionally substituted by one or more halo; the substituents represented by R₁ being the same or different when g is 2;



15


R₂ is H, an alkyl group containing 1 to 3 carbon atoms, or an alkoxy group containing 1 to 3 carbon atoms;

R₃ and R₄, which are the same or different, are H, or an alkyl group containing
 20 1 to 3 carbon atoms;

U is an alkylene chain containing 1 to 3 carbon atoms, optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms;

25 Q represents a divalent group of formula IIa, IIb or IIc





in which V is a bond or an alkylene chain containing 1 to 3 carbon atoms optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms;

- 5 V' is an alkylene chain containing 2 to 6 carbon atoms, optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms;

X is an alkylene chain containing 0 to 2 carbon atoms and X' is an alkylene chain containing 1 to 4 carbon atoms provided that the total number of carbon atoms
10 in X and X' amounts to 3 or 4; R₅ is H or an alkyl group containing 1 to 3 carbon atoms; and

T represents the group CO.HET in which HET is 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, 3- or 7-benzo[b]furanyl, 2,3-dihydro-7-
15 benzo[b]furanyl, 2-, 3- or 7-benzo[b]thiophenyl, 2- or 3-piperidyl, 3-, 4- or 5-pyrazolyl, 4- or 5-triazolyl, 5-tetrazolyl, 2-, 3- or 4-quinolyl, 2- or 4-quinazolinyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isothiazolyl or 2-, 4- or 5-thiazolyl each of which may be optionally substituted by one or more substituents selected from a) halo,
20 halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) hydroxy, f) an acyloxy group containing 1 to 3 carbon atoms, g) hydroxymethyl, h) cyano, i) an alkanoyl group containing 1 to 6 carbon atoms, j) an alkoxycarbonyl group containing 2 to 6 carbon atoms, k) a
25 carbamoyl group or carbamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, l) a sulphamoyl or sulphamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, m) an amino group optionally substituted by one or two alkyl groups each containing 1 to 5 carbon atoms, or n) 1-pyrrolidinyl or 1-
30 piperidinyl.

In preferred compounds of formula I, A is -O-.

In preferred compounds of formula I, B is -O-.

In more preferred compounds of formula I, both A and B are -O-.

5

In preferred compounds of formula I, g is 0 or 1. When g is 1, R₁ is preferably halo or an alkyl group containing 1 to 3 carbon atoms.

In preferred compounds of formula I, G₁-G₂-G₃ are -NH-CH=CH-.

10

In preferred compounds of formula I, R₂ is H or an alkyl group containing 1 to 3 carbon atoms. In more preferred compounds of formula I, R₂ is H.

15 In preferred compounds of formula I, R₃ and R₄, which are the same or different, are H or methyl. In more preferred compounds of formula I, R₃ and R₄ are both H.

In preferred compounds of formula I, U is methylene.

20

In preferred compounds of formula I, in which Q is a group of formula IIa or IIc, V is methylene or ethylene.

In preferred compounds of formula I, in which Q is a group of formula IIb, V' is an alkylene chain containing 2 to 4 carbon atoms.

25

In more preferred compounds of formula I, Q is a group of formula IIc in which X and X' are both ethylene, and V is methylene.

30 In preferred compounds of formula I, R₅ is H or methyl. In more preferred compounds of formula I, R₅ is H.

In preferred compounds of formula I, T is the group CO.HET in which HET is 2-, 3- or 4-pyridyl optionally substituted by one or more substituents selected from methoxy, trifluoromethyl, halo or an amino group optionally substituted by one or two

alkyl groups each containing 1 to 3 carbon atoms. In more preferred compounds of formula I in which T is CO.HET, HET is 3-pyridyl substituted by an amino group, or 2-pyridyl.

5 In a group of preferred compounds of formula I, G_1 - G_2 - G_3 are $-NH-C(R'')=CH-$, $-NH-N=CH-$ or $-NH-CH=N-$; R'' is H, CO_2Et , $CONH_2$, $CONMe_2$, $COMe$, CN , or CHO ; A and B are both $-O-$; g is 0; R_2 , R_3 and R_4 are all H; U is methylene; Q is a group of formula IIa or IIc in which V is methylene and X and X' are both ethylene; and T is the group CO.HET in which HET is 2-pyridyl, 3-pyridyl, 3-(2-amino)pyridyl, or 3-(2-methoxy)pyridyl.

Compounds of formula I may exist as salts with pharmaceutically acceptable acids. Examples of such salts include hydrochlorides, hydrobromides, sulphates, methanesulphonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [eg
15 (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino acids such as glutamic acid. Compounds of formula I and their salts may exist in the form of solvates (for example hydrates).

Compounds of formula I and intermediates in their preparation contain one or
20 more chiral centres, and exist in different optically active forms. When compounds of formula I and intermediates in their preparation contain one chiral centre, the compounds exist in two enantiomeric forms and the present invention includes both enantiomers and mixtures of enantiomers. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of
25 diastereoisomeric salts which may be separated, for example, by crystallisation; formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for
30 example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesised by asymmetric synthesis using

optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation.

When a compound of formula I contains more than one chiral centre it may exist in diastereoisomeric forms. The diastereoisomeric pairs may be separated by methods known to this skilled in the art, for example chromatography or crystallisation and the individual enantiomers within each pair may be separated as described above. The present invention includes each diastereoisomer of compounds of formula I and mixtures thereof.

10

Certain compounds of formula I and their salts may exist in more than one crystal form and the present invention includes each crystal form and mixtures thereof. Certain compounds of formula I and their salts may also exist in the form of solvates, for example hydrates, and the present invention includes each solvate and mixtures thereof.

15

Specific compounds of formula I are:-

- 20 2-Amino-*N*-[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]-pyridine-3-carboxamide;
- N*-[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]pyridin-2-carboxamide;
- 25 Ethyl 2,3-dihydro-2-({4-[(2-pyridinecarboxamido)methyl]piperidino)methyl)-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxylate;
- Ethyl 2,3-dihydro-2-({4-[(3-pyridinecarboxamido)methyl]piperidino)methyl)-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxylate;
- 30 Ethyl 2-({4-[(2-amino-3-pyridinecarboxamido)methyl]piperidino)methyl)-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxylate;
- 35 2,3-Dihydro-2-({4-[(2-pyridinecarboxamido)methyl]piperidino)methyl)-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- 2,3-Dihydro-2-({4-[(3-pyridinecarboxamido)methyl]piperidino)methyl)-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- 40 2-({4-[(2-Amino-3-pyridinecarboxamido)methyl]piperidino)methyl)-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- 2,3-Dihydro-*N,N*-dimethyl-2-({4-[(2-pyridinecarboxamido)methyl]piperidino)methyl)-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxamide;

- 2,3-Dihydro-*N,N*-dimethyl-2-({4-[(3-pyridinecarboxamido)methyl]piperidino)methyl}-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- 5 2-({4-[(2-Amino-3-pyridinecarboxamido)methyl]piperidino)methyl}-2,3-dihydro-*N,N*-dimethyl-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- N*-{[1-(8-Acetyl-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]-methyl}pyridine-2-carboxamide;
- 10 *N*-{[1-(8-Acetyl-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]-methyl}pyridine-3-carboxamide;
- N*-{[1-(8-Acetyl-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]-methyl}-2-aminopyridine-3-carboxamide;
- 15 *N*-{[1-(8-Cyano-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]-methyl}pyridine-2-carboxamide;
- N*-{[1-(8-Cyano-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]-methyl}pyridine-3-carboxamide;
- 20 2-Amino-*N*-{[1-(8-cyano-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]methyl}pyridine-3-carboxamide;
- N*-{[1-(8-Formyl-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]-methyl}pyridine-2-carboxamide;
- 25 *N*-{[1-(8-Formyl-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]-methyl}pyridine-3-carboxamide;
- 30 2-Amino-*N*-{[1-(8-formyl-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]methyl}pyridine-3-carboxamide;
- N*-{[1-(2,3-Dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]methyl}-2-methoxypyridine-3-carboxamide;
- 35 *N*-{[1-(2,3-Dihydro-7*H*-1,4-dioxino[2,3-*e*]indazol-2-ylmethyl)-4-piperidyl]methyl}-pyridine-2-carboxamide;
- 40 *N*-{[1-(2,3-Dihydro-7*H*-1,4-dioxino[2,3-*e*]indazol-2-ylmethyl)-4-piperidyl]methyl}-pyridine-3-carboxamide;
- 2-Amino-*N*-{[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indazol-2-ylmethyl)-4-piperidyl]-methyl}pyridine-3-carboxamide;
- 45 *N*-{[1-(2,3-Dihydro-7*H*-1,4-dioxino[2,3-*e*]benzimidazol-2-ylmethyl)-4-piperidyl]-methyl}pyridine-2-carboxamide;
- N*-{[1-(2,3-Dihydro-7*H*-1,4-dioxino[2,3-*e*]benzimidazol-2-ylmethyl)-4-piperidyl]-methyl}pyridine-3-carboxamide;
- 50

2-Amino-*N*-{[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]benzimidazol-2-ylmethyl)-4-piperidyl]methyl}pyridine-3-carboxamide;

5 2,3-Dihydro-2-(*N*-{[1-(2-pyridylcarbonyl)-4-piperidyl]methyl}aminomethyl)-7*H*-1,4-dioxino[2,3-*e*]indole;

2,3-Dihydro-2-(*N*-{[1-(3-pyridylcarbonyl)-4-piperidyl]methyl}aminomethyl)-7*H*-1,4-dioxino[2,3-*e*]indole;

10 2-(*N*-{[1-(2-Chloro-3-pyridylcarbonyl)-4-piperidyl]methyl}aminomethyl)-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indole;

2-(*N*-{[1-(2-Amino-3-pyridylcarbonyl)-4-piperidyl]methyl}aminomethyl)-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indole;

15

and pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers.

20 Specific enantiomeric forms of compounds of formula I include:

(*S*)-2-Amino-*N*-{[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]methyl}-pyridine-3-carboxamide; and

25 (*S*)-*N*-{[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]methyl}-pyridine-2-carboxamide;

and pharmaceutically acceptable salts thereof.

30 The present invention also includes pharmaceutical compositions containing a therapeutically effective amount of a compound of formula I or a salt thereof together with a pharmaceutically acceptable diluent or carrier.

35 As used hereinafter, the term "active compound" denotes a compound of formula I or a salt thereof. In therapeutic use, the active compound may be administered orally, rectally, parenterally or topically, preferably orally. Thus the therapeutic compositions of the present invention may take the form of any of the known pharmaceutical compositions for oral, rectal, parenteral or topical administration. Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy. The compositions of the invention
40 may contain 0.1-99% by weight of active compound. The compositions of the

invention are generally prepared in unit dosage form. Preferably the unit dosage of active ingredient is 1-500 mg. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art.

5 Compositions for oral administration are the preferred compositions of the invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, syrups and aqueous or oil suspensions. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art. Tablets may be prepared by mixing the active compound with an
10 inert diluent such as calcium phosphate in the presence of disintegrating agents, for example maize starch, and lubricating agents, for example magnesium stearate, and tableting the mixture by known methods. The tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings
15 by known methods, for example by the use of cellulose acetate phthalate. Similarly, capsules, for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by conventional means and, if desired, provided with enteric coatings in a known manner. The tablets and capsules may conveniently each contain 1 to 500 mg of the active compound. Other
20 compositions for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxymethyl- cellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil.

25

 The active compound may be formulated into granules with or without additional excipients. The granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example water) before ingestion. The granules may contain disintegrants (for example a pharmaceutically acceptable
30 effervescent couple formed from an acid and a carbonate or bicarbonate salt) to facilitate dispersion in the liquid medium.

 Compositions of the invention suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa
35 butter or polyethylene glycol bases.

Compositions of the invention suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.

5

Compositions for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally. A suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, for example paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol. Alternatively the active compounds may be dispersed in a pharmaceutically acceptable cream or ointment base. The amount of active compound contained in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.

The compounds of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body. Internal sources include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as a suspension or solution in a pharmaceutically acceptable oil of the compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused. The support may be a single body containing all the compound or a series of several bodies each containing part of the compound to be delivered. The amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.

In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.

In the compositions of the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients.

5 The present invention also comprises the use of a compound of formula I as a medicament.

 The pharmaceutical compositions containing a therapeutically effective amount of a compound of formula I or a salt thereof may be used to treat depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders, anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity in human beings. Whilst the precise amount of active compound administered in such treatment will depend on a number of factors, for example the age of the patient, the severity of the condition and the past medical history and always lies within the sound discretion of the administering physician, the amount of active compound administered per day is in the range 1 to 1000 mg preferably 5 to 500 mg given in single or divided doses at one or more times during the day.


 A further aspect of the present invention provides the use of a compound of formula I in the manufacture of a medicament for treating depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, or spasticity in human beings.

 The present invention also provides a method of treating depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease,


obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, or spasticity in human beings which comprises the administration of a therapeutically effective amount of a compound of formula I to a patient in need thereof.

Processes for the preparation of compounds of formula I will now be described. These processes form a further aspect of the present invention. The processes are preferably carried out at atmospheric pressure. The substituents are as defined for formula I above unless otherwise stated.

Compounds of formula I in which Q is a group of formula IIa in which R_5 is H, and V is $(CH_2)_{n+1}$ wherein n is 0,1 or 2, and R'' and R''' are other than formyl may be prepared by the reaction of a compound of formula III




with a compound of formula IV



followed by reaction of the intermediate imine with a reducing agent, for example sodium borohydride.


Compounds of formula I in which Q is a group of formula IIa in which R_5 is H, and V is $(CH_2)_{n+1}$ wherein n is 0,1 or 2 may be prepared by the reaction of a compound of formula III with a compound of formula V




in which Y is a leaving group, for example toluene-4-sulphonyloxy, optionally in the presence of a suitable solvent, optionally in the presence of a base, for example potassium carbonate.

5

Compounds of formula I in which Q is a group of formula IIa in which R_5 is H, and V is $(CH_2)_{n+1}$ wherein n is 0, 1 or 2 may be prepared by reaction of a compound of formula VI




10 with a compound of formula VII



in which Z is a leaving group, for example toluene-4-sulphonyloxy, optionally in the presence of a suitable solvent, optionally in the presence of a base, for example potassium carbonate.

15

Compounds of formula I in which U is methylene and Q is a group of formula IIa in which R_5 is H, and V is $(CH_2)_{n+1}$ wherein n is 0, 1 or 2, and R'' and R''' are other than formyl may be prepared by reaction of a compound of formula VIII




20 with a compound of formula VI, followed by reduction of the intermediate imine with a suitable reducing agent, for example sodium borohydride.

Compounds of formula I in which R_5 is an alkyl group and R'' and R''' are other than formyl may be prepared by alkylation of a compound of formula I in which R_5 is H

with for example formaldehyde and formic acid, or an aldehyde and a reducing agent such as sodium cyanoborohydride.

Compounds of formula III may be prepared from compounds of formula IX



5


in which E together with the nitrogen atom to which it is attached is a suitable cyclic imide, for example a phthalimide, by acid or base catalysed hydrolysis or by cleavage with a reagent, for example hydrazine hydrate.

10

Compounds of formula IX in which E together with the nitrogen atom to which it is attached is a phthalimide may be prepared by reaction of a compound of formula VII in which Z is a leaving group, for example toluene-4-sulphonyloxy, with potassium phthalimide.

15


Compounds of formula IV may be prepared by reaction of a compound of formula X



in which R₆ is an alkoxy group containing 1 to 4 carbon atoms, with a reducing agent, for example sodium bis (2-methoxyethoxy)aluminium hydride in a solvent, for example toluene.


20

Compounds of formula X may be prepared by reaction of a compound of formula XI



25 with an acylating agent of formula X₂-CO.HET in which X₂ is a leaving group, for example halo, alkoxy, hydroxy or alkoxycarbonyloxy, in the presence of a base, for example triethylamine, or an amide bond forming agent, for example carbonyl diimidazole, in a suitable solvent such as dichloromethane.

Compounds of formula IV may also be prepared by oxidation of a compound of formula XII




5 with a suitable oxidising agent, for example oxalyl chloride/dimethyl sulphoxide.

Compounds of formula V in which Y is toluene-4-sulphonyloxy may be prepared by reaction of a compound of formula XII with a tosylating agent, for example toluene-4-sulphonyl chloride.

10


Compounds of formula XII may be prepared by reaction of a compound of formula XIII



15 with an acylating agent of formula $\text{X}_2\text{-CO.HET}$ in which X_2 is a leaving group, for example halo, alkoxy, hydroxy or alkoxycarbonyloxy, in the presence of a base, for example triethylamine, or an amide bond forming agent, for example carbonyl diimidazole, in a suitable solvent such as dichloromethane.

20 Compounds of formula XIII may be prepared by reduction of a compound of formula XI, in which R_6 is an alkoxy group containing 1 to 4 carbon atoms, with a reducing agent, for example lithium aluminium hydride.

Compounds of formula VI may be prepared by reaction of a compound of formula XIV




25

in which D is a protecting group, for example 5-bromo-2-hydroxybenzylidene, with an acylating agent of formula $\text{X}_2\text{-CO.HET}$ in which X_2 is a leaving group, for example halo, alkoxy, hydroxy or alkoxycarbonyloxy, in the presence of a base, for example triethylamine, or an amide bond forming agent, for example carbonyl diimidazole, in a suitable solvent such as dichloromethane, followed by removal of the protecting group, for example by acid-catalysed hydrolysis.

30

Compounds of formula XIV may be prepared by reaction of a compound of formula XV




5 with a protecting reagent, for example 5-bromo-2-hydroxybenzaldehyde.

Compounds of formula XV may be prepared by reduction of a compound of formula XI in which R_6 is NH_2 with a reducing agent, for example lithium aluminium hydride.


10

Compounds of formula VII in which Z is toluene-4-sulphonyloxy may be prepared by reaction of a compound of formula XVI




15 with a tosylating agent, for example toluene-4-sulphonyl chloride, optionally in the presence of a base, for example pyridine.

Compounds of formula XVI in which A and B are both -O-, R_2 , R_3 and R_4 are all H, and U is methylene may be prepared by reaction of a compound of formula XVII




20 in which Z is a leaving group, for example chloro or toluene-4-sulphonyloxy, with a compound of formula XVIII



in a suitable solvent, for example water or dimethylformamide in the presence of a base, for example sodium hydroxide. When an enantiomerically pure form of a

compound of formula XVII, for example (*R*)-glycidyl-4-toluenesulphonate, is used, the single (*S*)-enantiomer of a compound of formula XVI can be prepared.


- Compounds of formula XVI in which A and B are both -O-, U is methylene, and
 5 R₂, R₃ and R₄ are all H, may also be prepared by cyclisation of a compound of formula XIX



in which R is H or an alkyl group containing 1 to 4 carbon atoms, using a base, for example potassium carbonate.


10

Compounds of formula XIX may be prepared by oxidation of compounds of formula XX




- in which R is H or an alkyl group containing 1 to 4 carbon atoms, with a peroxyacid, for
 15 example 3-chloroperoxybenzoic acid.

Compounds of formula XX may be prepared by alkylating compounds of formula XXI



- in which R is H or an alkyl group containing 1 to 4 carbon atoms, with compounds of
 20 formula XVII, in which Z is a leaving group, for example chloro or toluene-4-sulphonyloxy, in a suitable solvent, for example dimethylformamide, in the presence of a base, for example potassium carbonate.


Compounds of formula XVI in which A and U are methylene, B is -O-, R₂ is H and R'' and R''' are H or cyano, may be prepared by reduction of a compound of formula XXII



5

with a reducing agent, for example borane-dimethyl sulphide complex.

Compounds of formula XXII may be prepared by reduction of a compound of formula XXIII




10

in which L is H with a reducing agent, for example hydrogen in the presence of a palladium-on-carbon catalyst.

Compounds of formula XXIII in which L is H may be prepared by acid or base-catalysed hydrolysis of a compound of formula XXIII in which L is an alkyl group containing 1 to 6 carbon atoms.

Compounds of formula XXIII in which L is an alkyl group may be prepared by reaction of a compound of formula XXI in which R is H with a compound of formula XXIV

20




in which L is an alkyl group containing 1 to 6 carbon atoms, in the presence of a base, for example 1,4-diazabicyclo[2.2.2]octane (DABCO).

Compounds of formula VIII may be prepared by oxidation of a compound of formula XVI in which U is methylene with a suitable oxidising agent, for example pyridinium chlorochromate or by reduction of a compound of formula XXV


25

19



with a suitable reducing agent, for example sodium bis(2-methoxyethoxy)aluminium hydride in a solvent, for example toluene.


- 5 Compounds of formula XXV in which A and B are both -O- may be prepared by reaction of a compound of formula XXVI



- in which Y is a leaving group, for example bromo, and L is an alkyl group containing 1 to 6 carbon atoms with a compound of formula XVIII, in the presence of a base, for example potassium carbonate.
- 10

- Compounds of formula XXV in which A is methylene, B is -O-, R2 is H and L is an alkyl group containing 1 to 6 carbon atoms may be prepared by reduction of a compound of formula XXIII in which L is an alkyl group containing 1 to 6 carbon atoms, with a suitable reducing agent, for example hydrogen in the presence of a palladium-on-carbon catalyst.
- 15

Compounds of formula I in which Q is a group of formula IIa may be prepared by reaction of compound of formula XXVII




- 20 in which D' is H, with a compound of formula VII in which Z is a leaving group, for example toluene-4-sulphonyloxy, optionally in the presence of a base, for example potassium carbonate, and optionally in a solvent, for example acetonitrile.

- 25 Compounds of formula XXVII in which D' is H may be prepared by deprotection of a compound of formula XXVII in which D' is a protecting group, for


example *tert*-butoxycarbonyl, for example by acid hydrolysis in the presence of an acid, for example trifluoroacetic acid.

- Compounds of formula XXVII in which D' is a protecting group may be prepared by reaction of a compound of formula XXVIII




- in which D' is a protecting group, for example *tert*-butoxycarbonyl, with a compound of formula X_2 -CO.HET in which X_2 is a leaving group, for example halo, alkoxy, hydroxy or alkoxycarbonyloxy, in the presence of a base, for example triethylamine, or an amide bond forming agent, for example carbonyl diimidazole, in a suitable solvent such as dichloromethane.

Compounds of formula XXVII in which D' is a protecting group and HET is of the formula XXIX




- in which Y completes a heteroaromatic ring and R is H or alkyl, may be prepared by reaction of a compound of formula XXVIII with a compound of formula XXX



- in which Y completes a heteroaromatic ring and R is H or an alkyl group, in a solvent, for example 1,2-dimethoxyethane.


Compounds of formula I in which Q is a group of formula IIb may be prepared by reaction of a compound of formula XXXI

21




with an acylating agent of formula $X_2\text{-CO.HET}$ in which X_2 is a leaving group, for example halo, alkoxy, hydroxy or alkoxycarbonyloxy, in the presence of a base, for example triethylamine, or an amide bond forming agent, for example carbonyl diimidazole, in a suitable solvent such as dichloromethane.

Compounds of formula I in which Q is a group of formula IIb may be prepared by reaction of a compound of formula VII in which Z is a leaving group, for example toluene-4-sulphonyloxy, with a compound of formula XXXII



in which D' is H, optionally in the presence of a base, for example potassium carbonate, and optionally in a solvent, for example acetonitrile.

Compounds of formula XXXI may be prepared from a compound of formula XXXIII



in which E together with the nitrogen atom to which it is attached is a cyclic imide, for example a phthalimide, by acid or base catalysed hydrolysis or by cleavage with a reagent, for example hydrazine hydrate.


20

Compounds of formula XXXIII in which E together with the nitrogen atom to which it is attached is a phthalimide and R_5 is H may be prepared by reaction of a compound of formula III with a haloalkyl phthalimide, for example N-(3-bromopropyl)phthalimide, optionally in the presence of a base, for example potassium carbonate.

Compounds of formula XXXII in which D' is H may be prepared by deprotection of a compound of formula XXXII in which D' is a protecting group, for example *tert*-butoxycarbonyl, for example by acid hydrolysis in the presence of an acid, for example trifluoroacetic acid.

5

Compounds of formula XXXII in which D' is a protecting group may be prepared by reaction of a compound of formula XXXIV



in which D' is a protecting group, for example *tert*-butoxycarbonyl, with a compound of formula X₂-CO.HET in which X₂ is a leaving group, for example halo, alkoxy, hydroxy or alkoxycarbonyloxy, in the presence of a base, for example triethylamine, or an amide bond forming agent, for example carbonyl diimidazole, in a suitable solvent such as dichloromethane.

Compounds of formula XXXII in which D' is a protecting group and HET is of the formula XXIX in which Y completes a heteroaromatic ring and R is H or alkyl, may be prepared by reaction of a compound of formula XXXIV with a compound of formula XXX in which Y completes a heteroaromatic ring and R is H or an alkyl group, in a solvent, for example 1,2-dimethoxyethane.

20

Compounds of formula I in which Q is a group of formula IIc may be prepared by reaction of a compound of formula XXXV




in which D' is H, with a compound of formula VII in which Z is a leaving group, for example toluene-4-sulphonyloxy, optionally in the presence of a base, for example potassium carbonate, and optionally in a solvent, for example acetonitrile, at a temperature in the range 0-200°C, preferably in the range 20-150°C.

Compounds of formula XXXV in which D' is H may be prepared by deprotection of a compound of formula XXXV in which D' is a protecting group, for

30

example *tert*-butoxycarbonyl, for example by acid hydrolysis in the presence of an acid, for example trifluoroacetic acid.


Compounds of formula XXXV in which D' is a protecting group may be prepared by reaction of a compound of formula XXXVI



in which D' is a protecting group, for example *tert*-butoxycarbonyl, with a compound of formula $\text{X}_2\text{-CO.HET}$ in which X_2 is a leaving group, for example halo, alkoxy, hydroxy or alkoxycarbonyloxy, in the presence of a base, for example triethylamine, or an amide bond forming agent, for example carbonyl diimidazole, in a suitable solvent such as dichloromethane.

Compounds of formula XXXV in which D' is a protecting group and HET is of the formula XXIX in which Y completes a heteroaromatic ring and R is H or alkyl, may be prepared by reaction of a compound of formula XXXVI with a compound of formula XXX in which Y completes a heteroaromatic ring and R is H or alkyl, in a solvent for example 1,2-dimethoxyethane.


Compounds of formula I in which Q is a group of formula IIc and HET is of the formula XXIX may be prepared by reaction of a compound of formula XXXVII



with a compound of formula XXX, for example pyrido[2,3-*d*][1,3]oxazine-2,4(1*H*)-dione optionally in the presence of a solvent, for example 1,2-dimethoxyethane.


Compounds of formula XXXVII in which R_5 is H may be prepared from compounds of formula XXXVIII

24




in which D is a protecting group, for example 5-bromo-2-hydroxybenzylidene, by acid or base catalysed hydrolysis.

- 5 Compounds of formula XXXVIII may be prepared by reaction of a compound of formula XXXIX



- in which D is a protecting group, for example 5-bromo-2-hydroxybenzylidene, with a compound of formula VII, optionally in the presence of a base, for example
10 triethylamine.

Compounds of formula XXXIX may be prepared by reaction of a compound of formula XL



- 15 with a protecting reagent, for example 5-bromo-2-hydroxybenzaldehyde.

- Compounds of formula VII in which $G_1-G_2-G_3$ are $-NH-CH=CH-$ are known (J.Med.Chem.,1992,35, pg 3058). Compounds of formula VII in which $G_1-G_2-G_3$ are other than $-NH-CH=CH-$ may be prepared by methods analogous to that disclosed in
20 the above reference by selecting the appropriate starting materials.

- Compounds of formula I in which HET is 2-amino-3-pyridyl may be prepared by the reaction of the corresponding compound of formula I in which HET is 2-chloro-3-pyridyl with aqueous ammonia solution.

25

The ability of compounds of formula I to interact with 5-hydroxytryptamine (5-HT) receptors has been demonstrated by the following test which determines the

ability of the compounds to inhibit tritiated ligand binding to 5-HT receptors in vitro and in particular to 5-HT_{1A} receptors.

Hippocampal tissue from the brains of male Charles River CD rats weighing
5 between 150-250 g were homogenised in ice-cold 50 mM Tris-HCl buffer (pH 7.7)
when measured at 25°C, 1:40 w/v) and centrifuged at 30,000 g at 4°C for 10 minutes.
The pellet was rehomogenised in the same buffer, incubated at 37°C for 10 minutes
and centrifuged at 30,000 g at 4°C for 10 minutes. The final pellet was resuspended
in 50 mM Tris-HCl buffer (pH 7.7) containing 4 mM CaCl₂, 0.1% L-ascorbic acid and
10 10 µM pargyline hydrochloride (equivalent to 6.25 mg wet weight of tissue/ml) and
used immediately in the binding assay. Aliquots (400 µl; equivalent to 2.5 mg wet
weight of tissue/tube) of this suspension were added to tubes containing the ligand (50
µl; 2 nM) and distilled water (50 µl; total binding) or 5-HT (50 µl; 10 µM; non-specific
binding) or test compound (50 µl; at a single concentration of 10⁻⁶ M or at 10
15 concentrations ranging from 10⁻¹¹-10⁻³ M). The ligand was [³H]8-hydroxy-2-
(dipropylamino)tetralin ([³H]8-OH-DPAT) and the mixture was incubated at 25°C for 30
minutes before the incubation was terminated by rapid filtration.

The filters were washed with ice-cold Tris-HCl buffer and dried. The filters
20 were punched out into vials, scintillation fluid added and radioactivity determined by
liquid scintillation counting. The percentage displacement of specific binding of the
tritiated ligand was calculated for the single concentration (10⁻⁶ M) of test compound.
Displacement curves were then produced for those compounds which displaced ≥50%
of specific binding of the tritiated ligand at 10⁻⁶ M using a range of concentrations of
25 the compound. The concentration which gave 50% inhibition of specific binding (IC₅₀)
was obtained from the curve. The inhibition coefficient K_i was then calculated using
the formula

$$30 \quad K_i = \frac{IC_{50}}{1 + ([\text{ligand}]/K_D)}$$

in which [ligand] is the concentration of the tritiated ligand used and K_D is the
35 equilibrium dissociation constant for the ligand.

The ability of compounds of formula I to interact with adrenoceptor binding sites has been demonstrated by the following test which determines the ability of the compounds to inhibit tritiated ligand binding to adrenoceptors in vitro and in particular α_1 -adrenoceptors.

Whole cortical tissue from the brains of male Charles River CD rats weighing between 150-250 g were homogenised in ice-cold 50 mM Tris-HCl, pH 7.6 (at 25°C; 1:40 w/v) and centrifuged at 1000 g at 4°C for 10 minutes. The supernatant was centrifuged at 30,000 g at 4°C for 10 minutes. The pellet was rehomogenised in 50 mM Tris-HCl, pH 7.6 (1:40 w/v) and centrifuged at 30,000 g at 4°C for 10 minutes. The final pellet was resuspended in 50 mM Tris-HCl, pH 7.6 (equivalent to 12.5 mg wet weight of tissue/ml) and used immediately in the binding assay. Aliquots (400 μ l; equivalent to 5 mg wet weight of tissue/tube) of this suspension were added to tubes containing the ligand (50 μ l; 0.1 nM) and distilled water (50 μ l; total binding) or phentolamine (50 μ l; 5 μ M; non-specific binding) or test compound (50 μ l; at a single concentration of 10^{-6} M or at 10 concentrations ranging from 10^{-11} - 10^{-3} M). The ligand was [7-methoxy- 3 H]prazosin and the mixture was incubated at 30°C for 30 minutes before the incubation was terminated by rapid filtration.

The filters were washed with ice-cold Tris-HCl buffer and dried. The filters were punched out into vials, scintillation fluid added and radioactivity determined by liquid scintillation counting. The percentage displacement of specific binding of the tritiated ligand was calculated for the single concentration (10^{-6} M) of test compound. Displacement curves were then produced for those compounds which displaced $\geq 50\%$ of specific binding of the tritiated ligand at 10^{-6} M using a range of concentrations of the compound. The concentration which gave 50% inhibition of specific binding (IC_{50}) was obtained from the curve. The inhibition coefficient K_i was then calculated using the formula

$$K_i = \frac{IC_{50}}{1 + ([\text{ligand}]/K_D)}$$

in which [ligand] is the concentration of the tritiated ligand used and K_D is the equilibrium dissociation constant for the ligand.

5 The ability of compounds of formula I to interact with dopamine receptors has been demonstrated by the following test which determines the ability of the compounds to inhibit tritiated ligand binding to dopamine receptors in vitro and in particular to the D_2 -like dopamine receptors.

10 Striatal tissue from the brains of male Charles River CD rats weighing between 140-250g were homogenised in ice-cold 50 mM Tris-HCl buffer (pH 7.7 when measured at 25°C) and centrifuged at 40,000 g for 10 minutes. The pellet was resuspended in Tris salts buffer (50 mM Tris-HCl buffer containing 120 mM NaCl, 5 mM KCl, 2 mM $CaCl_2$ and 1 mM $MgCl_2$ with the addition of 6 mM ascorbic acid; pH 7.7 when measured at 25°C), and again centrifuged at 40,000 g for 10 minutes. The
15 final pellet was stored at -80°C. Before each test the pellet was resuspended in Tris salts buffer (equivalent to 2 mg wet weight of tissue/ml). Aliquots (720 μ l; equivalent to 1.44 mg wet weight of tissue/tube) of this suspension were then added to tubes containing the ligand (40 μ l; 1 nM) and Tris salts buffer (40 μ l; total binding) or spiroperidol (40 μ l; 10 nM; non-specific binding) or test compound (40 μ l; at a single
20 concentration of 10^{-6} M or at 6 concentrations ranging from 10^{-11} - 10^{-4} M). The ligand was tritiated (S)-sulpiride and the mixture was incubated at 4°C for 40 minutes before the incubation was terminated by rapid filtration.

25 The filters were washed with ice-cold Tris-HCl buffer and dried. The filters were punched out in to vials, scintillation fluid added and were left for about 20 hours before being counted by scintillation spectrophotometry. The percentage displacement of specific binding of the tritiated ligand was calculated for the single concentration (10^{-6} M) of test compound. Displacement curves were then produced over a range of concentrations for those compounds which displaced $\geq 50\%$ of specific
30 binding of the tritiated ligand at 10^{-6} M. The concentration which gave a 50% inhibition of specific binding (IC50) was obtained from the curve. The inhibition coefficient K_i was then calculated using the formula

$$K_i = \frac{IC_{50}}{1 + ([\text{ligand}]/K_D)}$$

in which [ligand] is the concentration of the tritiated ligand used and K_D is the equilibrium dissociation constant for the ligand.

The K_i values obtained in the above tests for 5-HT_{1A}, α_1 , and D₂-like binding for each of the final products of Examples 1 and 2 hereinafter are given in Table I below.

TABLE 1

Example Number	K _i (nM) value for		
	5-HT _{1A}	D ₂ -like	α_1
1	3.1	7.6	12.4
2	99%	122%	93%

The % figures in Table 1 are for % displacement at 10⁻⁶M.

The invention is illustrated by the following Examples which are given by way of example only. The final product of Examples 1 and 2 were characterised by one or more of the following procedures: gas-liquid chromatography; high performance liquid chromatography; elemental analysis, nuclear magnetic resonance spectroscopy and infrared spectroscopy.

Example 1

Potassium carbonate (0.89 g) was added under nitrogen to a stirred solution of ethyl 4-formyl-5-hydroxyindole-2-carboxylate (1.50 g) in dry dimethylformamide (40 ml). A solution of (*R*)-glycidyl 4-toluenesulphonate (1.47 g) in dry dimethylformamide (30 ml) was then added and the mixture stirred at ambient temperature for 10 minutes, then at 60°C for 3 hours. The mixture was poured into water (400 ml) and extracted with ethyl acetate (3x200 ml). The combined extracts

were washed with brine (6x200 ml), dried over magnesium sulphate and the solvent evaporated under reduced pressure. The brown solid residue was purified by flash column chromatography on silica eluting with a 1:1 mixture of petroleum ether (b.p. 40-60°C) and ethyl acetate to give ethyl (*R*)-5-(2,3-epoxypropoxy)-4-formylindole-2-carboxylate (1.07 g) as an off-white solid; m.p. 152-154 °C.

A stirred solution of ethyl (*R*)-5-(2,3-epoxypropoxy)-4-formylindole-2-carboxylate (1.95 g; prepared by the method described above) in dichloromethane (40 ml) was cooled to 0°C. 3-Chloroperoxybenzoic acid (85%; 1.75 g) was then added in one portion followed by a solution of trifluoroacetic acid (0.77g) in dichloromethane (10 ml), in portions. The mixture was stirred at 0°C for 10 minutes and then at ambient temperature for 1 hour. The reaction mixture was diluted with dichloromethane (300 ml) , washed successively with saturated aqueous sodium bisulphite solution (100 ml), saturated aqueous sodium bicarbonate solution (3x150 ml), dried over sodium sulphate and the solvent evaporated. The solid residue was purified by flash chromatography on silica eluting with a 1:1 mixture of petroleum ether (b.p. 40-60°C) and ethyl acetate to give ethyl (*R*)-5-(2,3-epoxypropoxy)-4-formyloxyindole-2-carboxylate (1.55 g) as a pale yellow crystalline solid; m.p. 123-125°C.

20

Saturated aqueous potassium carbonate solution (200 ml) was added to a stirred solution of ethyl (*R*)-5-(2,3-epoxypropoxy)-4-formyloxyindole-2-carboxylate (22.0 g; prepared in a similar manner to that described above) in tetrahydrofuran (250 ml) and the mixture was stirred at room temperature for 72 hours. The mixture was poured into water (1000 ml) and extracted with ethyl acetate (4x400 ml). The combined extracts were dried over sodium sulphate and the solvent evaporated under reduced pressure to give ethyl (*S*)-2,3-dihydro-2-(hydroxymethyl)-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxylate (17.65 g) as a pale purple solid; m.p. 152-153°C.

25

A solution of lithium hydroxide monohydrate (0.94 g) in water (25 ml) was added to a stirred solution of the product from the previous reaction (2.95 g) in methanol (50 ml) under nitrogen and the resulting solution stirred at 60°C for 1 hour. The methanol was then removed by evaporation and water (80 ml) added. Hydrochloric acid (2M) was then added until the mixture was pH 2, and the resulting

30

precipitate collected by filtration, washed with water and dried to give (*S*)-2,3-dihydro-2-(hydroxymethyl)-7*H*-1,4-dioxino[2,3-*e*]indole-8-carboxylic acid (2.61g) as a solid; m.p. 216-217°C.

5 A flask containing the product from the previous reaction (2.60 g) was plunged into a pre-heated isomantle at 250°C under nitrogen and the material heated at 250-60°C for 30 minutes. The residue was cooled to ambient temperature, pre-absorbed from a methanol solution onto silica and purified by flash column chromatography on silica eluting with 1:1 mixture of petroleum ether (b.p. 40-
10 60°C) and ethyl acetate to give (*S*)-2,3-dihydro-7*H*-1,4-dioxino-[2,3-*e*]indol-2-ylmethanol (0.69 g) as a colourless syrup.

A solution of (*S*)-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethanol (0.75 g; prepared by the method described above) in dichloromethane (50 ml) was stirred
15 with cooling in an ice bath. 4-(Dimethylamino)pyridine (0.59 g) and 4-toluenesulphonyl chloride (0.84 g) were then added and the solution stirred at ambient temperature overnight. The mixture was diluted with dichloromethane (200 ml), washed successively with water (50 ml), saturated aqueous copper(II) sulphate solution (2x50 ml) and water (50 ml), then dried over sodium sulphate and the
20 solvent evaporated to give (*S*)-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl 4-toluenesulphonate (1.04 g) as a pale brown oil which solidified on standing.

Trifluoroacetic acid (10 ml) was added dropwise to a stirred solution of 2-amino-*N*-(1-*tert*-butoxycarbonylpiperid-4-yl)methylpyridine-3-carboxamide (0.40 g) in
25 dichloromethane (15ml) and the mixture stirred at room temperature for 2 hours. The solvent was evaporated under reduced pressure and the oily residue dissolved in dry acetonitrile (20 ml). Potassium carbonate (5.0 g) and a solution of the product from the previous reaction (0.41g) in dry acetonitrile (10 ml) were then added and the mixture heated under reflux with stirring for 24 hours. The cooled reaction
30 mixture was filtered and the solvent removed evaporated under reduced pressure. The residue was dissolved in dichloromethane (50 ml), washed with water (3x50 ml), dried over magnesium sulphate and the solvent evaporated. The residue was purified by flash chromatography on silica eluting with a 20:1 mixture of dichloromethane and methanol to give (*S*)-2-amino-*N*-[1-(2,3-dihydro-7*H*-1,4-


dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methylpyridine-3-carboxamide (0.27g):
m.p. 104-106°C, $[\alpha]_D^{25}$ -36.8° (c = 0.367 in MeOH).

Example 2

5

Trifluoroacetic acid (5 ml) was added to stirred solution of *N*-(1-*tert*-butoxycarbonyl)piperid-4-yl)methylpyridine-2-carboxamide (1.00g) in dichloromethane (20 ml) and the mixture stirred at room temperature for 2 hours. The solvent was evaporated under reduced pressure and the residue dissolved in dry acetonitrile (30 ml). Potassium carbonate (5.0 g) and a solution of (S)-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl 4-toluenesulphonate (1.00 g) in dry acetonitrile (15ml) were then added and the mixture heated under reflux with stirring for 24 hours. The cooled mixture was filtered and the solvent removed. The residue was dissolved in dichloromethane (300 ml), washed with water (100 ml), dried over sodium sulphate and the solvent evaporated. The residual pale brown oil was purified by flash column chromatography on silica eluting with a 9:1 mixture of ethyl acetate and methanol to give the product free base as a pale-yellow oil. A solution of the product in hot ethanol (5 ml) was treated with a hot solution of fumaric acid (0.15 g) in ethanol (10 ml) and the solution then evaporated under reduced pressure. The resulting solid was triturated with diethyl ether to give (S)-*N*-[[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]methyl]pyridine-2-carboxamide 1.3 fumarate, 0.25 diethyl ether, 1.0 hydrate (588 mg); m.p.122-5°C, $[\alpha]_D^{25}$ -23.3° (c = 0.391 in EtOH).

25 Examples 3-27




The following compounds are prepared in a similar manner to that described in Example 1, by selection of the appropriate compounds of formula VII and XXXV (D' in XXXV being H):

- 3 Ethyl 2,3-dihydro-2-((4-((2-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxylate
- 4 Ethyl 2,3-dihydro-2-((4-((3-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxylate
- 5 Ethyl 2-((4-((2-amino-3-pyridinecarboxamido)methyl)piperidino)methyl)-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indole-8-carboxylate
- 10 6 2,3-Dihydro-2-((4-((2-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide
- 7 2,3-Dihydro-2-((4-((3-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide
- 15 8 2-((4-((2-Amino-3-pyridinecarboxamido)methyl)piperidino)methyl)-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide
- 9 2,3-Dihydro-*N,N*-dimethyl-2-((4-((2-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide
- 20 10 2,3-Dihydro-*N,N*-dimethyl-2-((4-((3-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide
- 25 11 2-((4-((2-Amino-3-pyridinecarboxamido)methyl)piperidino)methyl)-2,3-dihydro-*N,N*-dimethyl-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide
- 12 *N*-([1-(8-Acetyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]pyridine-2-carboxamide
- 30 13 *N*-([1-(8-Acetyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]pyridine-3-carboxamide
- 14 *N*-([1-(8-Acetyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]-2-aminopyridine-3-carboxamide
- 35 15 *N*-([1-(8-Cyano-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]pyridine-2-carboxamide
- 40 16 *N*-([1-(8-Cyano-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]pyridine-3-carboxamide
- 17 2-Amino-*N*-([1-(8-cyano-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]pyridine-3-carboxamide
- 45 18 *N*-([1-(8-Formyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]pyridine-2-carboxamide
- 19 *N*-([1-(8-Formyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]pyridine-3-carboxamide
- 50 20 2-Amino-*N*-([1-(8-formyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl]pyridine-3-carboxamide

- | | |
|----|---|
| 21 | <i>N</i> -[1-(2,3-Dihydro-7 <i>H</i> -1,4-dioxino[2,3- <i>e</i>]indol-2-ylmethyl)-4-piperidyl]methyl)-2-methoxypyridine-3-carboxamide |
| 5 | 22 <i>N</i> -[1-(2,3-Dihydro-7 <i>H</i> -1,4-dioxino[2,3- <i>e</i>]indazol-2-ylmethyl)-4-piperidyl]-methyl]pyridine-2-carboxamide |
| 23 | <i>N</i> -[1-(2,3-Dihydro-7 <i>H</i> -1,4-dioxino[2,3- <i>e</i>]indazol-2-ylmethyl)-4-piperidyl]-methyl]pyridine-3-carboxamide |
| 10 | 24 2-Amino- <i>N</i> -[1-(2,3-dihydro-7 <i>H</i> -1,4-dioxino[2,3- <i>e</i>]indazol-2-ylmethyl)-4-piperidyl]methyl]pyridine-3-carboxamide |
| 25 | <i>N</i> -[1-(2,3-Dihydro-7 <i>H</i> -1,4-dioxino[2,3- <i>e</i>]benzimidazol-2-ylmethyl)-4-piperidyl]methyl]pyridine-2-carboxamide |
| 15 | 26 <i>N</i> -[1-(2,3-Dihydro-7 <i>H</i> -1,4-dioxino[2,3- <i>e</i>]benzimidazol-2-ylmethyl)-4-piperidyl]methyl]pyridine-3-carboxamide |
| 20 | 27 2-Amino- <i>N</i> -[1-(2,3-dihydro-7 <i>H</i> -1,4-dioxino[2,3- <i>e</i>]benzimidazol-2-ylmethyl)-4-piperidyl]methyl]pyridine-3-carboxamide |

The free bases of these compounds can be converted into pharmaceutically acceptable salts by methods well known in the art.

Examples 28-30



The following compounds are prepared in a similar manner to that described in Example 1, by selection of the appropriate compounds of formula VII and VI:

- | | |
|----|--|
| 28 | 2,3-Dihydro-2-(<i>N</i> -[1-(2-pyridylcarbonyl)-4-piperidyl]methyl)aminomethyl)-7 <i>H</i> -1,4-dioxino[2,3- <i>e</i>]indole; |
| 35 | 29 2,3-Dihydro-2-(<i>N</i> -[1-(3-pyridylcarbonyl)-4-piperidyl]methyl)aminomethyl)-7 <i>H</i> -1,4-dioxino[2,3- <i>e</i>]indole; |
| 30 | 2-(<i>N</i> -[1-(2-Chloro-3-pyridylcarbonyl)-4-piperidyl]methyl)aminomethyl)-2,3-dihydro-7 <i>H</i> -1,4-dioxino[2,3- <i>e</i>]indole; |

40

The free base of these compounds can be converted into a pharmaceutically acceptable salt by methods well known in the art.

Example 31

5

The following compound may be prepared by amination of example 30 above:


- 31 2-(*N*-[1-(2-Amino-3-pyridylcarbonyl)-4-piperidyl]methyl)aminomethyl)-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indole.

10

Preparation of Starting Materials

1) Compounds of Formula VII

15





These compounds, in which Z is toluene-4-sulphonyloxy, may be prepared by reaction of the appropriate compound of formula XVI in which A and B are both -O-, R₂, R₃ and R₄ are H, g is 0, U is methylene, and G₁-G₂-G₃ are as defined in Table 2.

20

TABLE 2

G ₁ - G ₂ -G ₃	For Example No.
-NH-C(CO ₂ Et)=CH-	3, 4, 5
-NH-C(CONH ₂)=CH-	6, 7, 8
-NH-C(CONMe ₂)=CH-	9, 10, 11
-NH-C(OMe)=CH-	12, 13, 14
-NH-C(CN)=CH-	15, 16, 17
-NH-C(CHO)=CH-	18, 19, 20
-NH-CH=CH-	21, 28, 29, 30
-NH-N=CH-	22, 23, 24

G ₁ - G ₂ -G ₃	For Example No.
-NH-CH=N-	25, 26, 27




2) Compounds of Formula XXXV


5

Compounds of formula XXXV in which D' is H and X and X' are both ethylene may be prepared by acid hydrolysis, with, for example, trifluoroacetic acid, of the product of the reaction of the compound of formula XXXVI, in which D' is a protecting group, for example *tert*-butoxycarbonyl, and X and X' are both ethylene with the appropriate compound of formula X₂-CO.HET, as defined in Table 3.

10

TABLE 3


X ₂ -CO.HET	For Example No.
	3, 6, 9, 12, 15, 18, 22, 25
	4, 7, 10, 13, 16, 19, 23, 26
	21




Compounds of formula XXXV in which D' is H and X and X' are both ethylene may be prepared by reaction of a compound of formula XXXVI, in which D' is a protecting group, for example *tert*-butoxycarbonyl, and X and X' are both ethylene with the appropriate compound of formula XXX as defined in Table 4, followed by acid hydrolysis with, for example, trifluoroacetic acid.

TABLE 4

10




XXX	For Example No.
	5, 8, 11, 14, 17, 20, 24, 27

3) Compounds of Formula VI

These compounds may be prepared by acid hydrolysis, with, for example, aqueous potassium hydrogen sulphate solution, of the product of the reaction of the compound of formula XIV, in which D is a protecting group, for example

benzylidene, with the appropriate compound of formula $X_2\text{-CO.HET}$ as defined in Table 5.

TABLE 5

$X_2\text{-CO.HET}$	For Example No.
	28
	29
	30, 31

5

4) Compounds of Formula XVI

Compounds of formula XVI in which R'' is H or CO_2Et may be prepared by
 10 cyclisation of the appropriate compound of formula XIX in the presence of potassium carbonate.

Compounds of formula XVI in which R'' is CO_2H may be prepared by
 15 hydrolysis of the corresponding compound of formula XVI in which R'' is CO_2Et .

Compounds of formula XVI in which R'' is H may also be prepared by
 20 decarboxylation of the corresponding compound of formula XVI in which R'' is CO_2H .

Compounds of formula XVI in which R'' is CONH_2 may be prepared by
 amination of the corresponding compound of formula XVI in which R'' is CO_2Et .

Compounds of formula XVI in which R'' is CONMe₂ may be prepared by amination of the corresponding compound of formula XVI in which R'' is CO₂Et.

Compounds of formula XVI in which R'' is CHO may be prepared by
5 reduction of the corresponding compound of formula XVI in which R'' is CO₂Et.

Compounds of formula XVI in which R'' is COMe may be prepared by reaction of the corresponding compound of formula XVI in which R'' is CO₂H with methyl lithium.
10

Compounds of formula XVI in which R'' is CN may be prepared by dehydration of the corresponding compound of formula XVI in which R'' is CONH₂.

Example 32

15 The use of compounds of the present invention in the manufacture of pharmaceutical compositions is illustrated by the following description. In this description the term "active compound" denotes any compound of the invention but particularly any compound which is the final product of one of the preceding Examples.

20

a) Capsules

In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose are de-aggregated and blended. The mixture is filled into
25 hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound.

b) Tablets

30 Tablets are prepared from the following ingredients.

	<u>Parts by weight</u>
Active compound	10
Lactose	190
Maize starch	22

Polyvinylpyrrolidone	10
Magnesium stearate	3

5 The active compound, the lactose and some of the starch are de-aggregated, blended and the resulting mixture is granulated with a solution of the polyvinylpyrrolidone in ethanol. The dry granulate is blended with the magnesium stearate and the rest of the starch. The mixture is then compressed in a tableting machine to give tablets each containing a unit dose or a part of a unit dose of active compound.

10 Enteric coated tablets

Tablets are prepared by the method described in (b) above. The tablets are enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanol:dichloromethane (1:1).


15

d) Suppositories

In the preparation of suppositories, 100 parts by weight of active compound is incorporated in 1300 parts by weight of triglyceride suppository base and the mixture
20 formed into suppositories each containing a therapeutically effective amount of active ingredient.

Claims

1) Compounds of formula I



5 including enantiomers and pharmaceutically acceptable salts thereof in which

A is methylene or -O-;

B is methylene or -O-;

10

G_1 - G_2 - G_3 represent -N(R')-C(R'')=N-, -N=C(R'')-N(R')-, -N(R')-C(R'')=C(R''')-,
 -C(R''')=C(R'')-N(R')-, -N(R')-N=C(R'')-, -C(R'')=N-N(R')-, -N(R')-N=N-, -N=N-N(R')-,
 -N=C(R'')-O-, -N=C(R'')-S-, -O-C(R'')=N-, -S-C(R'')=N-, -O-N=C(R'')-, -S-N=C(R'')-,
 -C(R'')=N-O-, -C(R'')=N-S-, -S-C(R'')=C(R''')-, -C(R'')=C(R''')-S-, -O-C(R'')=C(R''')-,
 15 or -C(R'')=C(R''')-O-;

R' is H or an alkyl group containing 1 to 3 carbon atoms;

R'' and R''', which are the same or different, are H; halo; an alkyl group
 20 containing 1 to 3 carbon atoms optionally substituted by one or more halo; carboxy; an
 alkanoyl group containing 1 to 6 carbon atoms; an alkoxycarbonyl group in which the
 alkoxy group contains 1 to 3 carbon atoms; formyl; cyano; or a carbamoyl group or
 carbamoylmethyl group each optionally *N*-substituted by one or two alkyl groups each
 containing 1 to 3 carbon atoms;

25

g is 0, 1 or 2;

R₁ represents an alkyl group containing 1 to 3 carbon atoms optionally substituted by
 one or more halo; an alkoxy group containing 1 to 3 carbon atoms optionally
 30 substituted by one or more halo; halo; or an alkylthio group containing 1 to 3 carbon


atoms optionally substituted by one or more halo; the substituents represented by R_1 being the same or different when g is 2;

R_2 is H, an alkyl group containing 1 to 3 carbon atoms, or an alkoxy group
5 containing 1 to 3 carbon atoms;



R_3 and R_4 , which are the same or different, are H, or an alkyl group containing 1 to 3 carbon atoms;

10 U is an alkylene chain containing 1 to 3 carbon atoms, optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms;

Q represents a divalent group of formula IIa, IIb or IIc



15



20 in which V is a bond or an alkylene chain containing 1 to 3 carbon atoms optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms;

V' is an alkylene chain containing 2 to 6 carbon atoms, optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms;

25 X is an alkylene chain containing 0 to 2 carbon atoms and X' is an alkylene chain containing 1 to 4 carbon atoms provided that the total number of carbon atoms in X and X' amounts to 3 or 4; R_5 is H or an alkyl group containing 1 to 3 carbon atoms; and

T represents the group CO.HET in which HET is 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, 3- or 7-benzo[b]furanyl, 2,3-dihydro-7-benzo[b]furanyl, 2-, 3- or 7-benzo[b]thiophenyl, 2- or 3-piperidyl, 3-, 4- or 5-pyrazolyl, 4- or 5-triazolyl, 5-tetrazolyl, 2-, 3- or 4-quinolyl, 2- or 4-quinazolinyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isothiazolyl or 2-, 4- or 5-thiazolyl each of which may be optionally substituted by one or more substituents selected from a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) hydroxy, f) an acyloxy group containing 1 to 3 carbon atoms, g) hydroxymethyl, h) cyano, i) an alkanoyl group containing 1 to 6 carbon atoms, j) an alkoxycarbonyl group containing 2 to 6 carbon atoms, k) a carbamoyl group or carbamoylmethyl group each optionally *N*-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, l) a sulphamoyl or sulphamoylmethyl group each optionally *N*-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, m) an amino group optionally substituted by one or two alkyl groups each containing 1 to 5 carbon atoms, or n) 1-pyrrolidinyl or 1-piperidinyl.

2) Compounds of formula I as claimed in claim 1 in which A is -O-, B is -O-, g is 0 or 1, R₁ is halo or an alkyl group containing 1 to 3 carbon atoms, G₁-G₂-G₃ are -NH-CH=CH-, R₂ is H or an alkyl group containing 1 to 3 carbon atoms. R₃ and R₄, which are the same or different, are H or methyl, U is methylene, Q is a group of formula IIa or IIc, V is methylene or ethylene, X and X' are both ethylene, R₅ is H or methyl, and T is the group CO.HET in which HET is 2-, 3- or 4-pyridyl optionally substituted by one or more substituents selected from methoxy, trifluoromethyl, halo or an amino group optionally substituted by one or two alkyl groups each containing 1 to 3 carbon atoms.

3) Compounds of formula I as claimed in claim 1 selected from:

30

2-Amino-N-[[1-(2,3-dihydro-7H-1,4-dioxino[2,3-e]indol-2-yl)methyl]-4-piperidyl]methyl]-pyridine-3-carboxamide;

35

N-[[1-(2,3-dihydro-7H-1,4-dioxino[2,3-e]indol-2-yl)methyl]-4-piperidyl]methyl]pyridine-2-carboxamide;

Ethyl 2,3-dihydro-2-((4-((2-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-e]indol-8-carboxylate;

- Ethyl 2,3-dihydro-2-((4-((3-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxylate;
- 5 Ethyl 2-((4-((2-amino-3-pyridinecarboxamido)methyl)piperidino)methyl)-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indole-8-carboxylate;
- 2,3-Dihydro-2-((4-((2-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- 10 2,3-Dihydro-2-((4-((3-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- 2-((4-((2-Amino-3-pyridinecarboxamido)methyl)piperidino)methyl)-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- 15 2,3-Dihydro-*N,N*-dimethyl-2-((4-((2-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- 20 2,3-Dihydro-*N,N*-dimethyl-2-((4-((3-pyridinecarboxamido)methyl)piperidino)methyl)-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- 2-((4-((2-Amino-3-pyridinecarboxamido)methyl)piperidino)methyl)-2,3-dihydro-*N,N*-dimethyl-7H-1,4-dioxino[2,3-*e*]indole-8-carboxamide;
- 25 *N*-((1-(8-Acetyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl)pyridine-2-carboxamide;
- N*-((1-(8-Acetyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl)pyridine-3-carboxamide;
- 30 *N*-((1-(8-Acetyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl)-2-aminopyridine-3-carboxamide;
- N*-((1-(8-Cyano-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl)pyridine-2-carboxamide;
- 35 *N*-((1-(8-Cyano-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl)pyridine-3-carboxamide;
- 40 2-Amino-*N*-((1-(8-cyano-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl)pyridine-3-carboxamide;
- N*-((1-(8-Formyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl)pyridine-2-carboxamide;
- 45 *N*-((1-(8-Formyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl)pyridine-3-carboxamide;
- 2-Amino-*N*-((1-(8-formyl-2,3-dihydro-7H-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl)methyl)pyridine-3-carboxamide;
- 50

- N*-{[1-(2,3-Dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]methyl}-2-methoxypyridine-3-carboxamide;
- 5 *N*-{[1-(2,3-Dihydro-7*H*-1,4-dioxino[2,3-*e*]indazol-2-ylmethyl)-4-piperidyl]methyl}-pyridine-2-carboxamide;
- N*-{[1-(2,3-Dihydro-7*H*-1,4-dioxino[2,3-*e*]indazol-2-ylmethyl)-4-piperidyl]methyl}-pyridine-3-carboxamide;
- 10 2-Amino-*N*-{[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indazol-2-ylmethyl)-4-piperidyl]methyl}pyridine-3-carboxamide;
- N*-{[1-(2,3-Dihydro-7*H*-1,4-dioxino[2,3-*e*]benzimidazol-2-ylmethyl)-4-piperidyl]methyl}pyridine-2-carboxamide;
- 15 *N*-{[1-(2,3-Dihydro-7*H*-1,4-dioxino[2,3-*e*]benzimidazol-2-ylmethyl)-4-piperidyl]methyl}pyridine-3-carboxamide;
- 20 2-Amino-*N*-{[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]benzimidazol-2-ylmethyl)-4-piperidyl]methyl}pyridine-3-carboxamide;
- 2,3-Dihydro-2-(*N*-{[1-(2-pyridylcarbonyl)-4-piperidyl]methyl}aminomethyl)-7*H*-1,4-dioxino[2,3-*e*]indole;
- 25 2,3-Dihydro-2-(*N*-{[1-(3-pyridylcarbonyl)-4-piperidyl]methyl}aminomethyl)-7*H*-1,4-dioxino[2,3-*e*]indole;
- 2-(*N*-{[1-(2-Amino-3-pyridylcarbonyl)-4-piperidyl]methyl}aminomethyl)-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indole; and
- 30 2-(*N*-{[1-(2-Chloro-3-pyridylcarbonyl)-4-piperidyl]methyl}aminomethyl)-2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indole;
- and pharmaceutically acceptable salts thereof in the form of individual enantiomers,
- 35 racemates, or other mixtures of enantiomers.
- 4) A compound of formula I as claimed in claim 3, which is
- (*S*)-2-Amino-*N*-{[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]methyl}-pyridine-3-carboxamide; or
- 40 (*S*)-*N*-{[1-(2,3-dihydro-7*H*-1,4-dioxino[2,3-*e*]indol-2-ylmethyl)-4-piperidyl]methyl}-pyridin-2-carboxamide.
- 45 5) Compounds of formula I as claimed in claim 1, in which G₁-G₂-G₃ are -NH-C(R'')=CH-, -NH-N=CH- or -NH-CH=N-; R'' is H, CO₂Et, CONH₂, CONMe₂, COMe,

CN, or CHO; A and B are both -O-; g is 0; R₂, R₃ and R₄ are all H; U is methylene; Q is a group of formula IIa or IIc in which V is methylene and X and X' are both ethylene; and T is the group CO.HET in which HET is 2-pyridyl, 3-pyridyl, 3-(2-amino)pyridyl, or 3-(2-methoxy)pyridyl.

5

6) A pharmaceutical composition containing a therapeutically effective amount of a compound of formula 1 or a salt thereof as claimed in claim 1, together with a pharmaceutically acceptable diluent or carrier.

10 7) A compound of formula I, as claimed in claim 1, for use as a medicament.

8) A compound of formula I, as claimed in claim 7, for use as a medicament in the treatment of depression, anxiety, psychoses, tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug
15 abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, or spasticity in human beings.

20


9) The use of a compound of formula I, as claimed in claim 1, in the manufacture of a medicament for treating depression, anxiety, psychoses, tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia,
25 obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, or spasticity in human beings.

30 10) A method of treating depression, anxiety, psychoses, tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent
35 diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the


46

neuroendocrine system, stress, prostatic hypertrophy, or spasticity in human beings which comprises the administration of a therapeutically effective amount of a compound of formula I, as claimed in claim 1, to a patient in need thereof.

- 5 11) A process for the preparation of compounds of formula I, as claimed in claim 1, in which Q is a group of formula IIc, comprising the reaction of a compound of formula VII



- 10 in which Z is a leaving group and the other substituents are as defined for formula I, with a compound of formula XXXV



in which D' is H, X and X' are both ethylene, and the other substituents are as defined for formula I, optionally in the presence of a base.

15

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/05637

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D491/056 A61K31/44 C07D498/04 C07D513/04 C07D495/04
C07D493/04 //(C07D491/056,319:00),(C07D491/056,319:00,
231:00),(C07D491/056,319:00,235:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 07274 A (BOOTS) 16 March 1995 see page 1, paragraph 1; claim 1 ---	1,8
A	WO 91 13872 A (UPJHON) 19 September 1991 see claims 1,8 -----	1,8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

16 April 1997

Date of mailing of the international search report

21.04.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

In international application No.

PCT/EP 96/05637

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 10
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see annex
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 96/ 05637

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

On grounds of Article 6 and 17.2a(11) of the PCT (conciseness of claims) and of the Guidelines for Examination in the EPO, Part B, Chapter III, 2.2 (economic reasons) the search has been restricted to a generalisation of the preparation examples disclosed in the description, namely benzodioxine derivatives.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/05637

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9507274 A	16-03-95	AU 7692894 A	27-03-95
		BG 100388 A	31-07-96
		BR 9407413 A	12-11-96
		CN 1133043 A	09-10-96
		CZ 9600614 A	11-09-96
		EP 0717739 A	26-06-96
		FI 961016 A	05-03-96
		JP 9502431 T	11-03-97
		NO 960888 A	05-03-96
		PL 313347 A	24-06-96
		SI 9420058 A	31-12-96
		ZA 9406798 A	06-04-95
WO 9113872 A	19-09-91	AU 639536 B	29-07-93
		AU 7303091 A	10-10-91
		CA 2075057 A	16-09-91
		EP 0594593 A	04-05-94
		US 5302599 A	12-04-94